Sponsor Dossier
Boehringer Ingelheim
Sponsor Dossier for Boehringer Ingelheim. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ACTILYSE
- Brand: ATROVENT
- Brand: ESOVYND
- Brand: GIOTRIF
- Brand: GLYXAMBI
- Brand: JARDIAMET
- Brand: JARDIANCE
- Brand: METALYSE
- Device (sponsor): Medicine administration kit, oral
- Device (sponsor): Medication transfer set
- Device (sponsor): Medication transfer set
- Device (sponsor): Medicine administration kit, <specify>
- Device (sponsor): Inhaler, aerosol, portable
- Device (sponsor): Unclassified
- Device (sponsor): Unclassified
About
Boehringer Ingelheim is an Australian Private Company with ABN 52000452308, registered in NSW, with active entity status. The company trades under the names Boehringer Ingelheim Pty Ltd, Paladin Pharma, Altoria Pharma, and Zenith Pharma.
Portfolio
Boehringer Ingelheim has 26 brands on the ARTG, of which 21 are indexable. The company has 20 brands with Product Information on file, 10 brands with PBAC outcomes on record, and 8 brands with AusPARs on record. Notable brands include Actilyse, Atrovent, Esovynd, Giotrif, Glyxambi, Jardiamet, Jardiance, Metalyse, Micardis, Mobic, Ofev, and Pradaxa.
Therapeutic focus
— Respiratory: 7 brands — Cardiology: 6 brands — Endocrinology: 4 brands — Oncology: 3 brands — Neurology: 2 brands — Haematology: 1 brand — Immunology: 1 brand — Urology: 1 brand — Infectious Disease: 1 brand
PBS footprint
Six brands in the Boehringer Ingelheim portfolio have at least one PBS-listed item, with the portfolio's latest PBS schedule date being 2026-05-01.
Regulatory activity
Boehringer Ingelheim's latest PBAC outcome occurred on 2025-05-01, with 10 brands having PBAC outcomes on record. The company's latest AusPAR was issued on 2024-02-06, with 8 brands holding AusPARs on record.